Home   Business   Life Science

Life Science




Inside the Cambridge lab in pole position to create a new coronavirus vaccine

Inside the Cambridge lab in pole position to create a new coronavirus vaccine

Inside the Cambridge lab in pole position to create a new coronavirus vaccine

Prof Jonathan Heeney, of the University of Cambridge and DIOSVax, explains the unique technology behind his approach.


Coronavirus expected to hit AstraZeneca results in China

Coronavirus expected to hit AstraZeneca results in China

Coronavirus expected to hit AstraZeneca results in China

The biopharmaceutical company reports a year of strong revenue growth in 2019, but is braced for ‘unfavourable impact’ from Covid-19 epidemic.


Coronavirus vaccine being created by Cambridge laboratory may offer best hope in tackling epidemic

Coronavirus vaccine being created by Cambridge laboratory may offer best hope in tackling epidemic

Coronavirus vaccine being created by Cambridge laboratory may offer best hope in tackling epidemic

Professor Jonathan Heeney, CEO of DIOSVax, says with the right resources it can move quickly.


Reversing osteoarthritis: Mogrify secures $1.1m to assess cartilage regeneration therapy

Reversing osteoarthritis: Mogrify secures $1.1m to assess cartilage regeneration therapy

Reversing osteoarthritis: Mogrify secures $1.1m to assess cartilage regeneration therapy

The Cambridge Science Park-based company is transforming cell therapies with its technology.


Abcam acquires gene-editing platform from US biotech Applied StemCell

Abcam acquires gene-editing platform from US biotech Applied StemCell

Abcam acquires gene-editing platform from US biotech Applied StemCell

The Cambridge Biomedical Campus company has also purchased the oncology product portfolio.


How Turbine is bringing the winds of change to drug discovery

How Turbine is bringing the winds of change to drug discovery

How Turbine is bringing the winds of change to drug discovery

It has created a Simulated Cell platform capable of simulating hundreds of millions of experiments.


AstraZeneca launches $1bn strategy to be zero carbon by 2025 - and it will plant an AZ Forest with 50 million trees

AstraZeneca launches $1bn strategy to be zero carbon by 2025 - and it will plant an AZ Forest with 50 million trees

AstraZeneca launches $1bn strategy to be zero carbon by 2025 - and it will plant an AZ Forest with 50 million trees

The Cambridge-based biopharmaceutical aims for its supply chain to be carbon negative by 2030.


Stemnovate offers ‘unique’ multi-organ drug screening on reprogrammed human cells

Stemnovate offers ‘unique’ multi-organ drug screening on reprogrammed human cells

Stemnovate offers ‘unique’ multi-organ drug screening on reprogrammed human cells

The Babraham Research Campus company provides an alternative to animal testing using liver, heart, brain, pancreas and immunological cells.


Cancer Research UK to fund clinical trial of Bicycle Therapeutics immuno-oncology candidate

Cancer Research UK to fund clinical trial of Bicycle Therapeutics immuno-oncology candidate

Cancer Research UK to fund clinical trial of Bicycle Therapeutics immuno-oncology candidate

CRUK suggests the molecule could offer improved anti-tumor activity with fewer side effects compared to antibody-based approaches.


Cambridge Design Partnership works on new robotic surgery system with Titan Medical

Cambridge Design Partnership works on new robotic surgery system with Titan Medical

Cambridge Design Partnership works on new robotic surgery system with Titan Medical

A rival to CMR Surgical’s Versius, the SPORT system is focused on using single incisions.


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More